mAb Hit Generation

Monoclonal antibodies (mAbs) are highly specific immune molecules that bind to distinct targets. When seeking a mAb tailored to your target, diversity is key—it's the foundation for discovering high-affinity, functionally relevant candidates. Unlike conventional immunization regimens that often yield limited variability, Immunovive’s proprietary immunization protocol is engineered to unlock a broader and more diverse panel of antibodies. By optimizing both the immunization strategy and the capture process, our technology consistently delivers a richer pool of candidates, increasing the likelihood of identifying rare, high-performance binders.